How I Use It: The Exosome Diagnostics (EPI) prostate cancer biomarker utility in urology and primary care.
Can J Urol
; 29(4): 11224-11230, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1989837
ABSTRACT
Prostate-specific antigen (PSA) screening remains the mainstay for early detection of prostate cancer. Although PSA is a nonspecific prostate cancer biomarker, its specificity for high grade prostate cancer can be enhanced by pre-biopsy liquid biomarkers including the Exosome Dx Prostate IntelliScore (EPI) test. EPI is a stand-alone urine genomic test that measures 3 exosome-derived gene expression signatures without the need for digital rectal examination (DRE) or inclusion of standard of care parameters in the test algorithm. EPI has broad clinical utility as a risk stratification tool for clinically significant high grade prostate cancer in men considering diagnostic prostate biopsy (MRI-targeted and systematic biopsy). During the COVID-19 pandemic, the EPI At-Home Collection Kit was introduced and quickly became an important component of tele-urology. The EPI test has emerged as a prioritization tool for primary care referral to urologists and for prostate biopsy scheduling. EPI provides an objective and actionable genomic risk assessment tool for high grade prostate cancer and is a critical part of the informed decision-making regarding biopsy (targeted, systematic or both) in both urology and primary care practices.
Keywords
Search on Google
Collection:
International databases
Database:
MEDLINE
Main subject:
Primary Health Care
/
Prostatic Neoplasms
/
Urology
/
Exosomes
/
Self-Testing
Type of study:
Diagnostic study
/
Prognostic study
/
Systematic review/Meta Analysis
Limits:
Humans
/
Male
Language:
English
Journal:
Can J Urol
Journal subject:
Urology
Year:
2022
Document Type:
Article
Affiliation country:
United States
Similar
MEDLINE
...
LILACS
LIS